Press Releases

Year 2010

Wockhardt’s Q4 Results 2009   Consolidated Sales: Rs. 889 crore Operating Profits: Rs 134 crore Wockhardt’s UK & India branded business posts double-digit growth   January 25, 2010 Wockhardt receives US FDA approval for antibacterial Levofloxacin     January 13, 2010 Wockhardt receives US FDA approval for Alzheimer’s drug Memantine     January 06, 2010

Year 2009

Wockhardt launches anti-hypertensive drug Nicardipine injections in USA     November 18, 2009 Wockhardt’s Q3 Results 2009   Consolidated Sales grew to Rs. 923 crore Operating Profit (EBIDTA) at Rs. 182 crore   October 31, 2009 Wockhardt receives US FDA approval for Prostate drug Alfuzosin tablets     October 01, 2009 Wockhardt receives US FDA approval for Prostate drug Tamsulosin capsules     September 29, 2009 Wockhardt wins Government of India Patent Award   70 Patents Granted: 15 Indian and 55 International   September 24, 2009 Wockhardt divests its Veterinary business to Vétoquinol     August 20, 2009 Wockhardt’s Q2 Results 2009   Consolidated Sales at Rs. 954 crore Operating Profit (EBIDTA) at Rs. 168 crore   July 30, 2009 Wockhardt signs agreements to divest its Nutrition businesses to Abbott   Deal covers India’s leading paediatric and adult nutritional brands Farex and Protinex   July 28, 2009 Wockhardt signs agreement to divest its Animal Health Division     June 29, 2009 Wockhardt divests its German Business     June 17, 2009 Wockhardt appoints BDO Haribhakti as auditor     May 29, 2009 Wockhardt announces Entacapone patent settlement with Orion Corporation     April 29, 2009 Wockhardt’s 2008 Annual Results   Consolidated sales grew by 35.4% to Rs. 3,593 crores. Operating Profits (EBITDA) grew by 26.5% to Rs. 808 crores. • Mark-to-Market losses at Rs 581 crores • Overseas acquisitions grew significantly and got accretive • Secured 23 ANDA approvals from the US FDA in 2008   April 24, 2009 Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala   Dr. Murtaza Khorakiwala is Managing Director Huzaifa Khorakiwala is Executive Director   April 01, 2009 Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes     February 27, 2009 Wockhardt to launch generic version of ulcer drug Ranitidine syrup in the US market     February 26, 2009 Wockhardt to launch generic version of migraine drug Sumatriptan in the US market     February 17, 2009 Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market     February 12, 2009 Wockhardt to launch Divalproex ER in the US market   Gets US FDA approval for generic version of epilepsy drug   February 11, 2009 A biotechnology breakthrough in Diabetes   Wockhardt launches new insulin (Glaritus) in India. First in the world after innovator   February 10, 2009 Wockhardt conducts EGM to raise Rs. 500 Crores by issuance of Redeemable Preference Shares     January 19, 2009 Wockhardt signs in-licensing agreement with a Swiss firm for Bonistein   In-licensing deal to market Bonistein, a patented product, specially designed for Osteoporosis   January 14, 2009

Press Releases Archives Year 2008 Year 2007

For press enquiries about Wockhardt, please contact Daryl Suchitha Associate Vice President - Corporate Relations Wockhardt Limited Wockhardt Towers, Bandra-Kurla Complex, Bandra East, Mumbai 400 051, India. Tel. : + 91 - 22 - 2653 4444.    Extension: 6303 Direct Tel.: + 91 - 22 - 2659 6303 Fax: + 91 - 22 - 2653 4242 Email: daryls@wockhardt.com

Disclaimer:
The company would like to caution that any forward-looking statements or projections made by the company, including those made in the press release announcements, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.